Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,836
archived clinical trials in
Leukemia

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Immanuel Medical Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Immanuel Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Creighton University Medical Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Mount Sinai Hospital
mi
from
New York, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Faxton Regional Cancer Center
mi
from
Utica, NY
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Faxton Regional Cancer Center
mi
from
Utica, NY
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Pardee Memorial Hospital
mi
from
Hendersonville, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Pardee Memorial Hospital
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Cancer Care Associates - Mercy Campus
mi
from
Oklahoma City, OK
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Cancer Care Associates - Mercy Campus
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Miriam Hospital
mi
from
Providence, RI
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Mountainview Medical
mi
from
Berlin, VT
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Mountainview Medical
mi
from
Berlin, VT
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Danville Regional Medical Center
mi
from
Danville, VA
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
mi
from
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
Click here to add this to my saved trials
Lactation Outcomes Among Survivors of Pediatric Cancer
Lactation Outcomes Among Survivors of Pediatric Cancer
Status: Enrolling
Updated:  12/8/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Lactation Outcomes Among Survivors of Pediatric Cancer
Lactation Outcomes Among Survivors of Pediatric Cancer
Status: Enrolling
Updated: 12/8/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated:  12/8/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated: 12/8/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated:  12/8/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Status: Enrolling
Updated: 12/8/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies
Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia
Status: Enrolling
Updated:  12/10/2015
Massey Cancer Center
mi
from
Richmond, VA
High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies
Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia
Status: Enrolling
Updated: 12/10/2015
Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia
A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia
Status: Enrolling
Updated:  12/10/2015
University of New Mexico Health Sciences Center
mi
from
Albuquerque, NM
A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia
A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia
Status: Enrolling
Updated: 12/10/2015
University of New Mexico Health Sciences Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase I/II Study of the Combination of 5-azacitidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/14/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase I/II Study of the Combination of 5-azacitidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/14/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/15/2015
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/15/2015
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/15/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/15/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Ucla Department Of Medicine
mi
from
Los Angeles, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Ucla Department Of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Kaiser Permanente Medical Center
mi
from
Vallejo, CA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Kaiser Permanente Medical Center
mi
from
Vallejo, CA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
University of Chicago
mi
from
Chicago, IL
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
University of Kansas Medical Center
mi
from
Westwood, KA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
University of Kansas Medical Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Dana Faber Cancer Institute
mi
from
Boston, MA
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Dana Faber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated:  12/16/2015
Wayne State University
mi
from
Detroit, MI
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Status: Enrolling
Updated: 12/16/2015
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials